In our study, patients with T2D had well-controlled HbA1c levels on metformin and pioglitazone (mean baseline HbA1c of 6.6% ± 0.6%), which allowed us to study the impact of SGLT2 inhibitors on NAFLD rather than glycemic control. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.